AU2003284111A1 - Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol - Google Patents
Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterolInfo
- Publication number
- AU2003284111A1 AU2003284111A1 AU2003284111A AU2003284111A AU2003284111A1 AU 2003284111 A1 AU2003284111 A1 AU 2003284111A1 AU 2003284111 A AU2003284111 A AU 2003284111A AU 2003284111 A AU2003284111 A AU 2003284111A AU 2003284111 A1 AU2003284111 A1 AU 2003284111A1
- Authority
- AU
- Australia
- Prior art keywords
- hdl cholesterol
- dose effects
- gene haplotypes
- atorvastatin dose
- itgb3 gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 1
- 101150044523 ITGB3 gene Proteins 0.000 title 1
- 229960005370 atorvastatin Drugs 0.000 title 1
- 235000012000 cholesterol Nutrition 0.000 title 1
- 102000054766 genetic haplotypes Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41774302P | 2002-10-09 | 2002-10-09 | |
| US60/417,743 | 2002-10-09 | ||
| PCT/US2003/032361 WO2004033710A2 (en) | 2002-10-09 | 2003-10-09 | Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003284111A8 AU2003284111A8 (en) | 2004-05-04 |
| AU2003284111A1 true AU2003284111A1 (en) | 2004-05-04 |
Family
ID=32094078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003284111A Abandoned AU2003284111A1 (en) | 2002-10-09 | 2003-10-09 | Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003284111A1 (en) |
| WO (1) | WO2004033710A2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110010824A (en) | 2003-01-14 | 2011-02-07 | 아레나 파마슈티칼스, 인크. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as metabolic modulators, and the prevention and treatment of disorders associated therewith, including diabetes and hyperglycemia |
| EP2287166A3 (en) | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| ES2995737T3 (en) | 2015-01-06 | 2025-02-11 | Arena Pharm Inc | Compound for use in treating conditions related to the s1p1 receptor |
| US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
| WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| KR102859841B1 (en) | 2018-06-06 | 2025-09-12 | 아레나 파마슈티칼스, 인크. | Treatment of conditions associated with the S1P1 receptor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
-
2003
- 2003-10-09 AU AU2003284111A patent/AU2003284111A1/en not_active Abandoned
- 2003-10-09 WO PCT/US2003/032361 patent/WO2004033710A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004033710A2 (en) | 2004-04-22 |
| WO2004033710A3 (en) | 2004-11-18 |
| AU2003284111A8 (en) | 2004-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003203029A1 (en) | Improved health-related devices and methods | |
| AU2003272227A1 (en) | Patient support system and elements thereof | |
| AU2003258195A1 (en) | Modular computer system and components therefor | |
| AU2003220819A1 (en) | Plasma processor electrode and plasma processor | |
| AU2003209226A1 (en) | Adiponectin gene therapy | |
| AU2003299581A1 (en) | Antibodies against drugs of abuse | |
| AU2003211489A1 (en) | Remedies for liver diseases, hyperlipemia and diabetes | |
| AU2003235956A1 (en) | Quinazoline derivative and medicine | |
| AU2003232821A1 (en) | Novel phospholipases and uses thereof | |
| AU2003277910A1 (en) | Ocular gene therapy | |
| AU2003284111A1 (en) | Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol | |
| AU1824201A (en) | Polymorphisms in the human HMG-COA reductase gene | |
| AU2003283790A1 (en) | Display panel and large display using such display panel | |
| AU2002303230A1 (en) | Combined hydrotreating and process | |
| AUPS271902A0 (en) | Gene expression and multiple sclerosis | |
| AU2002953223A0 (en) | Novel therapeutic molecules and uses thereof | |
| AU2003302173A1 (en) | Spirotetrathiocarbamates and spirooxothiocarbamates | |
| AU2002951611A0 (en) | Cholesterol efflux and uses thereof | |
| AU2002953516A0 (en) | Genetic therapy and genetic modification | |
| AU2003228397A1 (en) | HAUSP-p53 INTERACTION AND USES THEREOF | |
| AU2003228990A1 (en) | Hydroxyphosphonates and phosphonophosphates as apolipoprotein e modulators | |
| AU2002254742A1 (en) | Haplotypes of the aldob gene | |
| AU2003214300A1 (en) | Composition used for combating cholesterol and improving digestion | |
| AU2003202553A1 (en) | Genetic polymorphisms predicting cardiovascular disease and medication efficacy | |
| AU2003252991A1 (en) | INTERFERON-Alpha INDUCED GENE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |